Join Mission PD for a Virtual Educational Presentation

sponsored by Medtronic

Tuesday

May 13, 2025

3:15 PM- 4:15 PM

Medtronic's adaptive deep brain stimulation (aDBS) technology, including BrainSense Adaptive DBS and BrainSense Electrode Identifier, has received FDA approval for use in Parkinson's disease patients. This system is designed to personalize therapy in real time by continuously monitoring and adjusting stimulation based on a patient's brain activity. This approach aims to optimize symptom control and potentially reduce side effects compared to traditional continuous DBS.



Meredith Spindler received her B.A. and M.D. from New York University, and completed her residency training at Weill-Cornell Medical College in New York. She came to the University of Pennsylvania for fellowship training in movement disorders at the Philadelphia VA PADRECC (Parkinson’s Disease Research, Education, and Clinical Center) and Pennsylvania Hospital. She joined the faculty at the Parkinson’s Disease and Movement Disorders Center (PD&MDC) in August 2012, where she treats patients with various movement disorders using medical therapies, device therapies, botulinum toxin injections, and deep brain stimulation, and teaches medical students, residents, and fellows. She is the Medical Director of the PD&MDC Deep Brain Stimulation program, and the site Principal Investigator for several clinical trials at PD&MDC. She has been a member of the Philadelphia Neurological Society since 2011.